Capecitabine

Related products

• 

  Colon cancer (mCRC)

  Panitumab

  【Product name】VECTIBIX

  [English common name]Panitumumab

  [Chinese common name]Panitumab

  [English name]

  [Chinese other name]

  [indications]Metastatic growth of epidermal growth factor receptor (EGFR) positive for disease progressionColon cancerpatient

  【Dosage】
  Recommended dosage:
  Panitumab: 6 mg/kg, intravenous infusion for more than 60 minutes, day 1 and every 2 weeks thereafter
  Method of administration:
  For intravenous infusion, the infusion rate should not be too fast. Do not give intravenous bolus or pill injection. During the infusion, observe whether there is an infusion reaction.
  Dosage adjustment and special instructions for use:
  (1) Panitumumab is not required for dermatological toxicity of grade 3 or higher or considered to be intolerant. If the ≤ 2 level does not improve the toxicity within 1 month, the panitumumab will be terminated forever.
  (2) If the dermatological toxicity is improved to ≤ 2, after no more than two doses of panitumumab are discontinued, the patient's symptoms are improved and the treatment can be resumed at 50% of the original dose. If the toxicity recurs, the panitumab will be terminated forever. If the toxicity does not recur, then the dose of panitumumab can be increased by 25% of the original dose until the recommended dose of 6 mg/kg is reached.

  [Storage] Store in the refrigerator (2 ° C – 8 ° C), do not freeze, store in the original carton to prevent strain.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Colon cancer (mCRC)

  Absip

  【Product name】EYLEA

  [English common name]Aflibercept

  [Chinese common name]Abbasid injection

  [English name]

  [Chinese other name]

  [Indications] late relapse / recurrenceColorectal cancerThe radical can not be removed.

  [Usage and Dosage] In combination with irinotecan hydrochloride hydrate, levofloxacin and fluorouracil, adults usually take 4mg/kg (body weight) once a week for 2 weeks, and use the instillation method to perform African claws within 60 minutes.蟾 (gene recombination) note. In addition, the weight is reduced according to the condition of the patient.

  [Storage] Store in the refrigerator (2 ° C to 8 ° C). Do not freeze. Keep the pre-filled syringe in its blister and outer carton to prevent light from shining. Unopened Eylea blisters can be stored at room temperature (less than 25 ° C) for up to 24 hours prior to use. After the blisters are opened, they are carried out under aseptic conditions.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Colon cancer (mCRC)

  Bevacizumab

  【Product name】Avastin, Cc-Pharma

  [English common name]Bevacizumab

  [Chinese common name]Bevacizumab

  [English name]

  [Chinese other name]

  [indications]
  TransferabilityColorectal cancer(mCRC): Combined with fluorouracil-based chemotherapy as first- or second-line treatment for metastatic colorectal cancer; combined with fluorouracil + irinotecan/oxaliplatin as second-line treatment for metastatic colorectal cancer after first-line therapy.
  2. Non-scalyNon-small cell lung cancer (NSCLC): Combination of carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer.
  3. Glioblastoma: Bevacizumab alone is effective in the treatment of glioblastoma in adults. The effectiveness of bevacizumab in glioblastoma is based on objective response rates.
  4. TransferabilityRenal cell carcinoma (MRCC): Combined with interferon alpha in the treatment of metastatic renal cell carcinoma.
  5. Cervical cancer: combined with paclitaxel + cisplatin or paclitaxel + topotecan.

  【Dosage】
  1. Metastatic colorectal cancer (mCRC), the recommended dose of bevacizumab: 5 mg / kg or 10 mg / kg, intravenous drip, once every 2 weeks.
  2. Non-squamous non-small cell lung cancer (NSCLC), the recommended dose of bevacizumab is: 15 mg / kg, once every 3 weeks, in combination with carboplatin + paclitaxel.
  3. Glioblastoma, the recommended dose of bevacizumab is: 10 mg / kg, once every 2 weeks.
  4. Metastatic renal cell carcinoma (MRCC), the recommended dose of bevacizumab is: 10 mg / kg, once every 2 weeks, combined with interferon alpha.
  5. Cervical cancer, the recommended dose of bevacizumab is: 15 mg / kg, once every 2 weeks, combined with paclitaxel + cisplatin or paclitaxel + topotecan.

  [Storage] Protected from light and stored and transported in the original packaging at 2°C-8°C. Do not store in cold storage. Don't shake.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.